Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine.

  • Elisabeth Barthell
  • Linn Wölber
  • Karin Hellner
  • Birka Camerer
  • Friederike Gieseking
  • Maik Hauschild
  • Ioannis Mylonas
  • Klaus Friese
  • Heather Sings
  • Radha Railkar
  • Christine Gause
  • Eliav Barr

Related Research units

Abstract

INTRODUCTION: As limited data among German women exist about HPV, Chlamydia trachomatis (CT) and Neisseria gonorrhoeae, we report the prevalence of these genital infections and general baseline demographics of the young German women enrolled in the phase III trials of the quadrivalent HPV vaccine. MATERIALS AND METHODS: German females (n = 437; 9-23 years) were recruited among 3 international phase 3 studies of an HPV-6/11/16/18 vaccine. We present baseline characteristics, prevalence of HPV-6/11/16/18 and, for women aged 16-23, abnormal cervical cytology and sexually transmitted diseases. RESULTS: Chlamydia trachomatis and Neisseria gonorrhoeae prevalence was 5 and 0.3%, respectively. Approximately 17% of participants had HPV-6, 11, 16, or 18 DNA or antibodies. All subjects

Bibliographical data

Original languageGerman
ISSN0932-0067
Publication statusPublished - 2008
pubmed 18936950